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Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing 
processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value 
of genetic testing and the shortcomings of current pathways to access testing. Approximately 15% of 
ovarian cancer patients have a germline BRCA1 or BRCA2 mutation which has substantial implications 
for their personal management and that of their relatives. Unfortunately, in most countries, routine 
implementation of BRCA testing for ovarian cancer patients has been inconsistent and largely 
unsuccessful. We developed a rapid, robust, mainstream genetic testing pathway in which testing is 
undertaken by the trained cancer team with cascade testing to relatives performed by the genetics 
team. 207 women with ovarian cancer were offered testing through the mainstream pathway. All 
accepted. 33 (16%) had a BRCA mutation. The result informed management of 79% (121/154) women 
with active disease. Patient and clinician feedback was very positive. The pathway offers a 4-fold 
reduction in time and 13-fold reduction in resource requirement compared to the conventional testing 
pathway. The mainstream genetic testing pathway we present is effective, efficient and patient-
centred. It can deliver rapid, robust, large-scale, cost-effective genetic testing of BRCA1 and BRCA2 and 
may serve as an exemplar for other genes and other diseases.
Ovarian cancer is diagnosed in 225,000 women and results in 140,000 deaths worldwide each year1. 
Approximately 10–15% of ovarian cancer is due to germline mutations in BRCA1 or BRCA2 (collectively termed 
“BRCA”), rising to 15–20% of non-mucinous ovarian cancer2–6. Determining the BRCA status of ovarian cancer 
patients has important therapeutic and prognostic implications7–10. Additionally, it provides improved cancer risk 
information for family members and opportunities for predictive gene testing and risk-reducing interventions, 
which is a cost-effective cancer prevention strategy11,12. In view of these benefits, several countries recommend 
that all women with non-mucinous or high-grade serous ovarian cancer have access to BRCA testing13–15.
Despite this recommendation the implementation of BRCA testing in ovarian cancer patients has been incon-
sistent and largely unsuccessful, with only 15–30% of eligible patients being offered testing16–19. This disappoint-
ing and unacceptably low rate is largely due to the complexities and limitations of systems through which ovarian 
cancer patients currently access BRCA testing. These arose through expansion of systems developed for testing 
healthy individuals with a family history of cancer, but they do not optimally serve the needs of individuals with 
cancer9. This is particularly true for women with ovarian cancer, for whom family history is recognised to be a 
poor triage for BRCA testing; many ovarian cancer patients with BRCA mutations do not have a strong family 
history of cancer2,5. Moreover, the rationales and timelines for testing in cancer patients, which is increasingly 
performed to personalise cancer treatment, differ from that of unaffected individuals. Testing access processes 
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need to be tailored accordingly. However, most centres use the same processes to access gene testing for individ-
uals with and without cancer18,20.
Recent technological, therapeutic and societal developments now make it imperative that modernized BRCA 
testing access processes for ovarian cancer patients are established. The advent of next-generation sequencing has 
made gene testing fast and affordable, removing the technological and economic barriers that previously hindered 
access. The recent approval of PARP inhibitors in the treatment of relapsed ovarian cancer in BRCA mutation 
carriers has further highlighted the clinical importance of testing10,21–24. Finally, the knowledge, awareness and 
expectations of women with ovarian cancer in relation to gene testing has greatly increased in recent years, with 
many more women wanting access to testing25,26.
Here, following wide consultation, we have developed and evaluated a rapid, robust, patient-centred, main-
stream genetic testing pathway to maximize availability, utility and equity of access to BRCA testing for women 
with ovarian cancer.
Results
Mainstream genetic testing pathway. Standard practice in many hospitals has been for cancer patients 
potentially eligible for genetic testing to be referred to a genetics team with whom they have discussions before 
and after testing. In response to the information gathered during the consultation process we developed a pathway 
in which members of the cancer team that had completed online training were able to directly consent patients 
for genetic testing (Fig. 1, Supplementary Appendix). In pathway v1 the result was returned to the cancer team 
and it was their responsibility to give the result to the patient; it was not stipulated how or when this happened. 
Women with a BRCA mutation were then sent a genetics appointment, which was to be within three weeks of 
receiving their result. This worked successfully for women with mutations, although it required the genetics team 
to repeatedly check to see when the result had been communicated so the genetics appointment letter could be 
sent. However, we found that the mutation-negative results were not consistently being communicated to patients 
in a timely fashion. After further consultation we revised the pathway, such that the test result was sent from the 
genetics team, in writing, to the patient and cancer team, together with the appropriate information sheet, and a 
genetics appointment for patients with a mutation. This ensured consistent, rapid communication of the results 
to all parties. Furthermore, it ensures that all women with mutations automatically receive a genetics appoint-
ment date with their result, typically within 3–4 weeks from the test initiation. This pathway was well received by 
patients and the medical teams, as demonstrated by the results of the feedback (Supplementary Tables 2 and 3). 
It has become the standard pathway for BRCA testing in ovarian cancer patients in our institution. The final path-
way is shown in Fig. 1. Comprehensive details of the full pathway are in the Supplementary Appendix.
Figure 1. Mainstream pathway for BRCA testing in ovarian cancer patients. 
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Patient characteristics. 207 women with ovarian cancer were offered BRCA testing through the main-
stream pathway between 07/2013–11/2014 (Table 1, Supplementary Table 1). All had non-mucinous ovarian 
cancer; 84% (173/207) had high grade serous cancer. The average age at diagnosis was 57 years (range 22–87). 67 
(32%) patients were seen during first-line treatment, 79 (38%) during treatment for disease relapse and 61 (29%) 
during a follow-up appointment whilst in remission and off treatment, of whom 10 subsequently relapsed. All 207 
women wanted testing and had testing; 200 (97%) consented to testing at first discussion. No woman requested 
a genetics appointment for additional discussion prior to testing. No clinician felt a woman needed additional 
discussions prior to testing. 37 women had a family history of a first or second degree relative with ovarian or 
breast cancer, of whom 31 would have been eligible for referral to genetics and testing based on 10% likelihood 
of having a mutation calculated according to Supplementary Fig. 3 12,27. Full details of the participants are given 
in Supplementary Table 1.
BRCA results. Pathogenic BRCA mutations were identified in 33 women (16%), 17 in BRCA1 and 
16 in BRCA2 (Table 1, Fig. 2, Supplementary Fig. 4 and Supplementary Table 1). Average age at diagno-
sis of BRCA mutation-positive individuals was 54 years (range 30–87)). This was not significantly different 
from the mutation-negative individuals (average age at diagnosis of 58 years (range 22–79; P = 0.052). All 
mutation-positive individuals had high grade cancers, 32 were serous and one was endometriod. 16 (42%) 
mutation-positive patients had a family history of breast or ovarian cancer in a first or second degree relative, 
though this had only been noted by the cancer team for 11 patients. Less than half (15/33, 45%) of the BRCA 
mutation-positive patients were eligible for testing based on standard genetics criteria (Supplementary Fig. 3), 
14 because of their family history and one because of their personal history of breast and ovarian cancer. 
Furthermore, only 15/39 (38%) patients in the full series eligible for testing based on genetics criteria had muta-
tions. Five BRCA mutation-positive patients had a second cancer: two previously had breast cancer (both BRCA1 
mutation carriers), one previously had melanoma and two had synchronous endometrial cancer (all BRCA2 
mutation-carriers). Thus 20% of individuals with ovarian cancer and another primary cancer had a BRCA muta-
tion, only two of whom were eligible for testing using standard genetics criteria (Supplementary Table 1).
Impact on patient management. The test result was considered useful in the management of 132/207 
(64%) women, including 123/156 (79%) women with active disease (i.e. tested during first-line treatment or 
relapse, including women tested whilst in remission who subsequently relapsed) (Fig. 2, Supplementary Table 1). 
For the mutation-positive individuals, the BRCA status impacted trial eligibility, with 20/23 women with BRCA 
mutations and active disease entered into PARP inhibitor trials, (two were too early in their disease course to be 
eligible for PARP inhibitor trials and one was ineligible). Furthermore, 31/32 women with mutations became 
eligible for enhanced breast surveillance (one woman previously had breast cancer and bilateral mastectomy). 
Several are also having discussions with regard to possible breast risk-reducing surgery. Of the 174 women with-
out a mutation the negative result was considered in management decisions of 100/132 (75%) with active disease, 
primarily in relation to eligibility for trials (n = 85), or choice of chemotherapy (n = 15). There was no alteration 
in clinical management of the 42 individuals without mutations tested during remission, unsurprisingly, but the 
information will likely be useful should they relapse in the future.
Category Sub-category No mutation BRCA1 BRCA2
Histology Serous 147 17 15
Endometroid 21 1
Clear cell 2
Mixed epithelial 4
Age at diagnosis Mean (range) 57.8 (22–81) 52.1 (30–76) 55.9 (43–87)
Grade Low 5
Intermediate 1
High 168 17 16
Stage I 23
II 13 1 3
III 107 14 11
IV 31 2 2
Time of testing 1st line treatment 54 8 5
Relapse 70 6 3
Remission 42 3 6
Remission (later relapsed) 8 2
Family history of breast cancer or 
ovarian cancer
No 153 7 10
Yes 21 10 6
BRCA status impact on treatment
No 74 1
Yes 100 17 15
Table 1. Summary of patient characteristics.
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Impact on family management. All 33 patients with a BRCA mutation attended their genetics appoint-
ment at which implications for themselves and their wider family was discussed, in accordance with standard 
procedures (Supplementary Fig. 5). As of June 2015, 63 relatives had undergone predictive testing, of whom 33 
had a BRCA mutation and 30 did not (Supplementary Fig. 4). A further 54 relatives are undergoing discussions. 
This is an average of 3.5 relatives per family (range 0–12). No mutation-negative patient requested a genetics 
appointment to discuss their results further. Two mutation-negative patients were referred to genetics because of 
their family history of cancer.
Patient and clinician experience. The patient experience of the mainstream pathway was very positive 
(Supplementary Fig. 2, Supplementary Table 2). The written information was felt to be clear and helpful and no 
patient reported feeling unclear as to why they were offered the test. 98% felt they were given sufficient time to 
think about whether they wanted a test and were aware the results could have implications for themselves (96%) 
and their family (98%). Most patients (88%) were aware that further discussions with genetics would be organised 
if a mutation was found, though fewer (76%) said they were aware they could have had additional discussions 
with genetics prior to deciding if to have testing. Nonetheless, all were happy to have had testing and 98% were 
happy to have had testing at one of their cancer clinic appointments rather than at a separate appointment with 
genetics. All patients with mutations found their genetics appointment helpful (Supplementary Table 2). The 
cancer team experience was also very positive. All 15 individuals felt comfortable offering and consenting for 
testing and felt it was possible to consent within the time constraints of a standard cancer clinic appointment 
(Supplementary Table 3).
Large-scale implementation and cost implications. About 6,500 new patients are diagnosed with 
non-mucinous ovarian cancer in UK each year. All are eligible for testing based on the 10% mutation prevalence 
threshold recommended by the National Institute for Health and Care Excellence (NICE)12. We conducted a 
review of UK practice shortly after the NICE recommendations were announced18. This revealed that a minority 
of ovarian cancer patients were receiving testing, primarily due to capacity limitations of genetics units together 
with the complexity of testing eligibility criteria, which impede referral. The traditional testing pathway requires 
13,000 genetics appointments per year as all patients typically have a pre and post-test consultation either in 
person or via telephone (Fig. 3). By contrast, the mainstream pathway requires ~1,000 genetics appointments 
(for individuals with mutations), a ~13-fold reduction, and providing a reduction in costs of ~£2.6 M per year20. 
Further cost savings would be generated in genetics as the proportion of unaffected individuals with an identified 
mutation in the family would increase; testing for a known mutation is 3–5× cheaper than undertaking the full 
gene analysis required if the family status is unknown20. The mainstream pathway also offers a ~4-fold reduction 
in time to the result because the average waiting time for a genetics appointment in UK is 12–15 weeks20 (Fig. 3). 
Use of the mainstream pathway would thus potentially allow large-scale implementation of BRCA testing in 
ovarian cancer patients, at a national level, with the existing clinical infrastructure.
Discussion
In this study, 16% of women with non-mucinous ovarian cancer had a BRCA mutation, adding further evidence 
that germline BRCA mutations are a significant cause of the disease2–6. We also show that stratifying access to 
testing for ovarian cancer patients should be determined by personal cancer history rather than family history. 
Family history performs poorly as an eligibility criterion; half of the BRCA mutation carriers we identified did not 
have a relevant family history, and only a third of women who met the standard gene testing criteria had a muta-
tion. Determining test eligibility on patient criteria is also much simpler to implement consistently. Moreover, 
Figure 2. Patient flow through mainstream pathway. 
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the BRCA result was considered useful in management planning of 79% of patients with active disease: 97% of 
patients with a mutation and 75% of patients without a mutation. This is consistent with increasing data showing 
that stratification of ovarian cancer by BRCA status can provide important clinical, therapeutic and prognostic 
information, and should be part of standard care7,8,10.
All 207 patients offered the mainstream testing pathway accepted it. None wanted an additional genetics 
appointment prior to deciding whether to have a test. Furthermore, the patient feedback showed patients were 
pleased they had testing, irrespective of the outcome, and were pleased they could access testing through a routine 
cancer clinic appointment. This reflects our consultation data, and other data, which show many women with 
ovarian cancer want flexible, simplified access to gene testing25,26. The cancer and genetics teams also had confi-
dence in the pathway and found it straight-forward to execute.
The complexity and the time and resource (cost and personnel) requirements intrinsic to most gene testing 
pathways has impeded routine access for ovarian cancer patients. The conventional pathway involves all cancer 
patients consulting genetics before and after testing. This hinders timely availability of results, and introduces 
multiple points for patients to be lost from the system before getting their result. Here, we have streamlined the 
pathway, without compromise of quality or patient care, by training the cancer team to provide information for 
patients to decide if they want to have a test. This allows genetics expertise to be concentrated where it is needed, 
namely the patients with mutations and anyone with questions that cannot be addressed by the cancer team. It 
is also convenient and appropriate in an era of increasing tumour genetic tests being ordered and consented for 
by cancer teams. Tumour testing can reveal variants that are germline cancer predisposition mutations. It is thus 
imperative that the consenting and patient management processes for germline and tumour testing are integrated. 
Additionally, the mainstream pathway greatly reduces the time, appointments and cost of gene testing compared 
to the conventional pathway. We estimate the reduction in pre-test genetics consultations alone would save the 
NHS > £2.6 M annually.
Change to a mainstream testing pathway will likely lead to some new challenges, at least in the short-term. 
For example, in the set-up phase, in addition to new ovarian cancer cases, surviving women with a previous diag-
nosis of ovarian cancer will also be eligible for testing. In the UK, there are ~25,000 such women for whom test 
resourcing will need to be secured. A longer term challenge relates to accuracy of risk information provided to 
unaffected relatives of BRCA mutation-carriers identified through ovarian cancer patient testing. The cancer risk 
figures typically used are derived from multi-case high-risk families. These can over-estimate the risks to relatives 
of mutation carriers identified in different contexts, for example testing of cancer patients, or as incidental find-
ings28,29. Reliable risk estimates in these other contexts are currently not available, and are urgently needed. That 
being said, given that no effective screening for ovarian cancer is available, the disease often presents at advanced 
stage and mortality is still considerable, it is likely that salpingectomy and oophorectomy, which reduces ovarian 
cancer risk by > 80%, will be an attractive option for many unaffected BRCA mutation-carriers identified through 
mainstream testing of ovarian cancer patients30,31. This is also likely to be cost-effective for healthcare systems 
given that existing data indicate the much more expensive conventional BRCA testing pathway is cost-effective at 
a 10% mutation detection threshold11,12. Of equal importance, it would expedite prevention of the thousands of 
ovarian cancers that occur due to germline BRCA mutations.
The mainstream gene testing pathway we describe here could be readily implemented, at a national level, 
in the UK and other countries. It is an effective, efficient, patient-centred pathway that allows genetic testing 
access for ovarian cancer patients to be increased in a consistent and equitable fashion. Several national and 
international centres are already adopting the principles and processes we describe for ovarian cancer patients. 
Furthermore, we are running a similar study for BRCA testing in breast cancer patients and are currently 
Figure 3. Comparison of time and appointment savings of UK-wide implementation of mainstream and 
traditional BRCA testing pathways. About 6,500 new patients are diagnosed with non-mucinous ovarian 
cancer in UK each year and are eligible for testing12. (a) In the mainstream pathway the testing can be completed 
in 3–4 weeks at existing cancer clinic appointments and only women with a mutation (~1000) have genetics 
follow-up. (b) In the traditional pathway all 6,500 patients have two genetics appointments for testing leading to 
substantial increases in the time and resources required.
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expanding the approach to accommodate gene panels. The principles could equally be applied to other cancer 
predisposition genes and other areas of genomic medicine, although uncertainties with respect to cancer risks 
and clinical implications present significant challenges in many disease areas9,29,32. To facilitate evaluation and 
adoption of the mainstream pathway we have made the components of our pathway fully and freely available in 
the Supplementary Appendix and on www.mcgprogramme.com.
Methods
Pathway design. To inform pathway design we undertook wide consultation with geneticists, genetic coun-
sellors, oncologists, cancer nurse specialists, genetics laboratories and patient representative groups throughout 
the UK through formal consultation days and informal information gathering18,26. The consultation process was 
informative and highlighted some key themes. First, all groups wanted more access to genetic testing for ovarian 
cancer patients. Second, there was strong support for more flexible, patient-centred access to testing, as long as 
the strengths of existing systems were retained, particularly with respect to obtaining informed consent. Third, 
all groups believed genetic testing reports should give clear and readily understandable information about the 
clinical actionability of the results18.
Using the consultation data we designed and iterated the pathway using lean methodology33. The pathway was 
approved by the Mainstreaming Cancer Genetics (MCG) programme board and the Royal Marsden gynaecolog-
ical cancer and genetics teams. Review of pathway performance was undertaken every six months. Mainstream 
pathway v1 was used from July 2013 to May 2014. Mainstream pathway v2 was used from May 2014 to Nov 2014 
and is now the standard BRCA gene testing pathway for ovarian cancer patients at the Royal Marsden Hospital 
(Fig. 1).
Participants. Participants were women with ovarian cancer seen between 07/2013–11/2014 who met the eli-
gibility criteria. Between 07/2013–05/2014 the eligibility criterion was women with non-mucinous ovarian cancer 
below 65 years. This age limit was employed to ensure testing capacity was available. In May 2014 the age limit was 
removed and the testing eligibility became, and remains, any woman with non-mucinous ovarian cancer.
Consent training. In response to the consultation we developed a web-based e-learning training module, 
which can be completed in < 30 minutes and is freely and easily accessible via computer, tablet or smartphone. 
The training includes videos, available on YouTube, and documentation about the pathway including a com-
prehensive frequently answered questions document. A certificate of training is provided on completion. No 
testing was permissible unless the training had been completed. The full training package is available on www. 
mcgprogramme.com/BRCA and detailed in the Supplementary Appendix.
BRCA gene testing. BRCA testing was performed by one of two methods: Sanger sequencing and MLPA 
for 127 tests before 24/03/2014, the TruSight Cancer Panel (TSCP) for 80 tests after 24/03/2014 both within the 
TGLclinical gene testing laboratory, which is accredited to ISO 15189 standards (www.TGLclinical.com). Full 
details of these methods are available on request. Both methods have > 99% sensitivity for small variants and 
exonic deletion and duplications. For both methods, pathogenic mutations were independently verified using a 
second aliquot of DNA by Sanger sequencing or MLPA, as appropriate. All predictive tests in relatives were also 
performed by Sanger or MLPA. All mutation-positive relatives had the same mutation that had been identified in 
the proband. The change in method simply reflected the evolution of TGLclinical to next-generation sequencing 
that occurred during the course of the study.
Interpretation of BRCA results was highlighted as a concern by both genetics and cancer teams18. Clarity 
about the pathogenicity and clinical relevance of variants was considered essential. In particular, using the term 
‘variant of uncertain/unknown significance’ (VUS) without further information about potential clinical man-
agement was considered confusing and liable to lead to inconsistent, inappropriate management as has been 
well-documented34,35. Availability of all the BRCA data, rather than just select variants, was also considered desir-
able, but structured to ensure clinically actionable variants were clearly highlighted.
To fulfil these requirements we developed a two-page report as shown in Supplementary Fig. 1. The first page 
is given to the patient, cancer and genetics teams and provides clear information about whether or not a patho-
genic mutation was detected. The second page provides information about all the BRCA variants detected and is 
available on request. Pathogenic mutations were defined as variants predicted to cause premature protein trunca-
tion through frameshifting small insertions or deletions, whole exon deletion/duplications, stop-gain (nonsense) 
or essential splice-site changes in BRCA1 (prior to c.5545) and BRCA2 (prior to c.9924) or other types of variant 
(e.g. nonsynonymous (missense) variants) for which conclusive genetic proof of pathogenicity equivalent to that 
associated with truncating mutations was available. If a variant was plausibly pathogenic and a specific evaluation 
could result in definitive classification, the variant was designated a Variant Requiring Evaluation (VRE) and the 
specific evaluation to be performed and the time-frame for definitive classification was outlined on the report. 
During this study one VRE was detected, a possible exonic deletion in BRCA2 that was likely artefactual as it 
was only detected by one MLPA kit. Repeat MLPA on a fresh sample confirmed that no deletion was present. 
All variants are also being submitted to databases to foster ongoing research. Any future reclassifications will be 
communicated to patients and their medical teams.
Outcomes. The outcomes assessed were: 1) If BRCA testing was performed, 2) Result of BRCA testing, 3) 
Impact on patient management, 4) Impact on family management, 5) Impact on genetics service resourcing, 6) 
Patient experience, 7) Clinician experience.
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Cost comparison. To estimate the cost of the new pathway compared to the traditional pathway we used the 
pathway data and costs from Slade et al.20. In the typical traditional pathway patients have a first appointment in 
genetics @£332.29 prior to testing and then a follow-up appointment to receive the test result @£127.38. The cost 
for 6,500 patients is thus £2,987,855. In the mainstream pathway the ~1,000 patients with a mutation have a first 
appointment with genetics @£332.29 to discuss the result so the total cost of genetics appointments is £332,290. 
Thus the mainstream pathway has an annual cost saving of £2,655,565. All other costs e.g. for the test, follow-up 
of the patient and cascade to relatives is the same in both pathways.
Evaluation of pathway experience. We sent questionnaires to all participants six months after pathway 
v1 was initiated and six months after v2 was initiated to facilitate pathway optimisation and to evaluate patient 
experience. This was conducted through a retrospective questionnaire survey using a 5-point Likert rating scale, 
and was approved by the Royal Marsden Clinical Audit Committee. Questionnaires were sent to 129 patients 
(Supplementary Fig. 2, Supplementary Table 2). The questionnaires for those with and without mutations and 
for those in pathway v1 vs pathway v2 were slightly different. Hence there were 4 questionnaires with 15–18 
questions including 13 core questions present in every questionnaire (Supplementary Fig. 2). Completed ques-
tionnaires were received from 108 patients (84% response rate), of which three had to be excluded (due to incon-
sistent completion) giving 89 questionnaires from women without a BRCA mutation and 16 from women with a 
mutation (Supplementary Table 2). Completed questionnaires were also received from 15 members of the cancer 
team (13 doctors and two clinical nurse specialists) that consented patients through the mainstream pathway 
(Supplementary Table 3).
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